Prescient Therapeutics Gains Momentum in PTX-100 Trials

Prescient Therapeutics Limited (AU:PTX) has released an update.

Prescient Therapeutics has reported a successful quarter with positive feedback from an international T-cell lymphoma conference on its Phase 1b study of PTX-100, and a complete response from the last patient in the trial. The company maintains a healthy cash reserve of $14.5 million and is refining the Phase 2 trial design with expert input to address unmet medical needs in T-cell lymphomas. Prescient plans to engage with the FDA for the upcoming Phase 2 trial, aiming for a commencement before year’s end, while also advancing their cell therapy platforms and cell therapy development activities.

For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.